# CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

> **NCT06365671** · PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 16 (estimated)

## Conditions studied

- B-cell Non Hodgkin Lymphoma

## Interventions

- **OTHER:** autologous stem-cell transplantation
- **DRUG:** Relmacabtagene autoleucel (relma-cel)

## Key facts

- **NCT ID:** NCT06365671
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-16
- **Primary completion:** 2026-04
- **Final completion:** 2027-04
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06365671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06365671, "CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06365671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*